Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report

Most cases of acute promyelocytic leukemia (APL) are driven by the PML::RARA fusion gene, which is sensitive to differentiation induction therapy comprising of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Treatment with ATRA plus ATO has achieved remarkable clinical outcome in patients...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Xianfeng Ouyang, Jianguo Yan, Su Hu, Wenfeng Zhu, Qibao Zhou, Fei Hu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Subjects:	acute promyelocytic leukemia variant APL TFG::RARA venetoclax all-trans retinoic acid arsenic trioxide
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1529640/full